Last reviewed · How we verify

NCT04495218: DIA

NGS Panel of Incomplete Forms of Ocular Albinism

Completed Last updated 19 September 2024
What this trial tests

trial testing Blood samples in Albinism, Ocular in 53 participants. Completed in 28 February 2024.

Timeline
23 November 2020
Primary endpoint
28 February 2024
28 February 2024

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
StatusCompleted
Study typeOBSERVATIONAL
Enrollment53
Start date23 November 2020
Primary completion28 February 2024
Estimated completion28 February 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

0 and older, any sex, with Albinism, Ocular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Implementation of a next-generation sequencing panel of genes to identify deleterious variants in patients with incomplete forms of albinism.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Crossed VEP asymmetry in a patient with AHR-linked infantile nystagmus and foveal hypoplasia.
    Smirnov VM, Smirnov VM, Lasseaux E, Michaud V, et al · · 2024 · cited 2× · PMID 38922562 · DOI 10.1007/s10633-024-09979-6

Verify or expand the search:

Other trials of Blood samples

Trials testing the same drug.

Other recruiting trials for Albinism, Ocular

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04495218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing